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able body weight, or placebo for up to 14 days. Injections wereMulticenter clinical trial of recombinant human insulin-like
started within six days of the onset of ARF. The primary end-growth factor I in patients with acute renal failure.
point was a change in glomerular filtration rate from baseline.Background. Patients with acute renal failure (ARF) have
Other end points included changes from baseline in urine vol-high morbidity and mortality rates, particularly if they have
ume, creatinine clearance and serum urea, creatinine, albuminserious comorbid conditions. Several studies indicate that in
and transferrin, frequency of hemodialysis or ultrafiltration,rats with ARF caused by ischemia or certain nephrotoxins,
and mortality rate.insulin-like growth factor-I (IGF-I) enhances the recovery of
Results. During the treatment period, which averaged 10.7 6renal function and suppresses protein catabolism.
4.1 and 10.6 6 4.5 days in the rhIGF-I and placebo groups,Methods. Our objective was to determine whether injections
there were no differences in the changes from baseline valuesof recombinant human IGF-I (rhIGF-I) would enhance the
recovery of renal function and is safe in patients with ARF. The of the glomerular filtration rate, creatinine clearance, daily
study was designed as a randomized, double-blind, placebo- urine volume, or serum urea nitrogen, creatinine, albumin or
controlled trial in intensive care units in 20 teaching hospitals. transferrin. In patients who did not receive renal replacement
Seventy-two patients with ARF were randomized to receive therapy, there was also no significant difference in serum creati-
rhIGF-I (35 patients) or placebo (37 patients). The most com- nine and urea between the two groups. Twenty patients in
mon causes of ARF in the rhIGF-I and placebo groups were, the rhIGF-I group and 17 placebo-treated patients underwent
respectively, sepsis (37 and 35% of patients) and hypotension dialysis or ultrafiltration. Twelve rhIGF-I–treated patients and
or hemodynamic shock (42 and 27% of patients). At baseline, 12 placebo-treated patients died during the 28 days after the
the mean (6 sd) APACHE II scores in the rhIGF-I and pla- onset of treatment.
cebo-treated groups were 24 6 5 and 25 6 8, respectively. In Conclusions. rhIGF-I does not accelerate the recovery of
the rhIGF-I and placebo groups, the mean (median) urine renal function in ARF patients with substantial comorbidity.
volume and urinary iothalamate clearances (glomerular filtra-
tion rate) were 1116 6 1037 (887) and 1402 6 1183 (1430)
ml/24 hr and 6.4 6 5.9 (4.3) and 8.7 6 7.2 (4.4) ml/min and
Acute renal failure (ARF) is a common event in hospi-did not differ between the two groups. Patients were injected
subcutaneously every 12 hours with rhIGF-I, 100 mg/kg desir- talized patients, particularly in those requiring intensive
care [1]. It is associated with an increased risk for morbid-
ity and mortality. The mortality rate in patients withKey words: ischemia, nephrotoxicity, protein catabolism, comorbidity
in ARF, hemodynamics. ARF tends to be strongly influenced by their underlying
comorbid conditions. The mortality rate in ARF patientsReceived for publication June 16, 1998
with comorbid conditions has been estimated to be asand in revised form November 13, 1998
Accepted for publication January 11, 1999 high as 80 to 85% in some series [1–4]. ARF also compli-
cates the medical management of hospitalized patients 1999 by the International Society of Nephrology
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and may itself contribute to morbidity and mortality. persistence of ARF after intravenous infusion of suffi-
Hence, a treatment that would accelerate the recovery cient fluids, if clinically indicated; a fractional excretion
of renal function in patients with ARF might be expected of sodium of 1.0% or greater in oliguric patients (urine
to reduce morbidity and possibly mortality, and could less than 500 ml/24 hr); and a commitment by the patient
reduce the cost of medical care. and medical staff for renal replacement therapy and ag-
Recombinant human insulin-like growth factor I gressive life-supporting measures, if medically indicated.
(rhIGF-I) is a 70-amino acid polypeptide growth factor Exclusion criteria included the following: the onset of
with structural homology to insulin. IGF-I is an anabolic ARF more than six days before commencement of the
agent that mediates many actions of growth hormone screening studies (discussed later in this article); irrevers-
and mimics some actions of insulin. In addition to its ible disease expected to result in a rapidly fatal outcome;
many metabolic effects, rhIGF-I increases renal blood an acute physiology and chronic health evaluation
flow and glomerular filtration rate (GFR) in rats, normal (APACHE II) score [20, 21] of greater than 37 during
adult humans, and patients with chronic renal failure the 24-hour period preceding screening; renal failure
[5–11]. rhIGF-I also accelerates the recovery of renal caused by obstruction of the urinary tract, x-ray contrast
function, enhances the healing of the injured nephron, nephropathy, or bilateral renal vascular obstruction.
and reduces mortality in animals with ischemic, toxic, or Other exclusion criteria were: chronic renal failure, the
endotoxin-induced experimental ARF [10, 12–17]. These hepatorenal syndrome, interstitial nephritis, or glomeru-
beneficial effects on the kidney appear to be due to lonephritis; renal allograft; solitary kidney; persisting hy-
the vasoactive, mitogenic, and other metabolic effects of potension (systolic blood pressure less than 90 mm Hg)
rhIGF-I [13, 18]. after fluid resuscitation and in the absence of afterload
In the doses currently used, rhIGF-I has been adminis- reduction or antihypertensive therapy; vasopressor treat-
tered by subcutaneous injections to normal subjects and ment within 12 hours of study entry (except for dopamine
patients with chronic renal failure with few side effects. at less than 10 mg/kg/min); known or suspected cancer
Because of its beneficial effects in rats with ARF and (except basal cell carcinoma) within the preceding two
apparent safety in humans, we examined whether years; known hypersensitivity to human insulin, rhIGF-I,
rhIGF-I will accelerate recovery from ARF in patients. iodine or shellfish; and pregnancy, HIV infection, or
A multicenter, double-blind, randomized, placebo-con- treatment with another investigational agent within the
trolled clinical trial was performed. Two hypotheses were preceding 28 days. This study was approved by the insti-
tested: (a) that rhIGF-I will increase the rate of recovery tutional review board for human research at each partici-
of renal function in patients with ARF, and (b) that pating center, and informed written consent was ob-
rhIGF-I can be administered safely to these individuals.
tained from each study participant or his/her family
members.
METHODS Upon entering the study, each patient underwent a
24-hour baseline screening period. During this period, aStudy protocol
detailed medical history was obtained. A physical exami-Twenty clinical centers participated in this trial. Pa-
nation was performed. The APACHE II score was calcu-tients with ARF were randomized to receive, in a double-
lated, and a chest x-ray, echocardiogram, complete bloodblinded fashion, subcutaneous injections of either
count, serum chemistry panel, urinalysis, and measure-rhIGF-I, 100 mg/kg desirable body wt, or equal volumes
ment of urine sodium, potassium, and creatinine wereof placebo every 12 hours at 9:00 a.m. and 9:00 p.m. The
obtained. The creatinine clearance and the GFR (iotha-injections were continued for 14 consecutive days. The
lamate clearance) were measured using fractional urineappearances of the rhIGF-I and placebo were indistin-
collections over a three-hour period.guishable. The bioactivity of each rhIGF-I batch that
Patients began treatment with rhIGF-I or placebowas used in this study had been tested in a standardized
after baseline measurements were completed. On eachassay measuring the mitogenic response of quiescent
day of the study, vital signs, 24-hour urine volume, andMG-63 cells, a human osteosarcoma cell line. Desirable
body weight were recorded. Complete blood counts andbody weight was determined from the Metropolitan Life
routine serum chemistries were obtained on each day ofInsurance Tables [19]. This report describes the results
study. Blood glucose was measured before and two hoursin 72 patients with ARF.
after each injection. At baseline and on days 4, 9, and 13Patients were accepted into the study if they satisfied
of the study, the clearances of iothalamate and creatininethe following criteria: age, 18 to 80 years; a diagnosis of
were measured as described later in this article. SerumARF, as defined by a rise in serum creatinine from a
IGF-I was measured at baseline and on days 4, 9, andbaseline value of less than 1.8 to 3.0 mg/dl or greater or
13 at approximately 12 hours after the most recent ad-an acute decrease in creatinine clearance to 25 ml/min
or less following surgery, trauma, hypotension, or sepsis; ministration of rhIGF-I or placebo. Serum IGF-binding
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protein (IGFBP)-2 and IGFBP-3 levels were measured ical laboratory of each participating center using routine
clinical laboratory methods. Serum samples for the IGF-Iat baseline and on days 1, 4, 8, 12, and 14.
Throughout the study, patients were provided with assay were frozen at 2208C and measured in a central
laboratory. Serum was chromatographed on a 0.9 3 100standard clinical care by their usual medical personnel.
Blood products and nonstudy medications were adminis- cm column containing Sephadex F-50 (fine), using 0.25 m
formic acid to separate IGF-I from its serum-bindingtered, and laboratory tests were obtained as medically
indicated. Patients were given adequate nutritional sup- proteins as previously described [22]. Serum IGF-I was
measured by a specific radioimmunoassay that used anport by either the enteral or parenteral route with an
attempt to provide energy intakes of 2000 to 2500 kcal/ antiserum kindly provided by Drs. L.E. Underwood and
J.J. Van Wyk (Chapel Hill, NC, USA) and distributedday and 1.0 to 1.5 g/kg of protein. The decision to begin
renal replacement therapy (hemodialysis or continuous for research use through the National Hormone and
Pituitary Program. Serum anti-IGF-I antibodies werevenovenous hemodiafiltration) was made by individual
study physicians using the following rules as determined measured in the rhIGF-I–treated patients using an en-
zyme-linked immunosorbent assay (ELISA) as pre-in the study protocol: acidemia (serum bicarbonate con-
centration of less than 12 mm), hyperkalemia (serum viously described [23]. Serum IGFBP-2 levels were mea-
sured by ELISA as previously described [24, 25], andpotassium of more than 6.5 mm), rapid rise in serum
urea nitrogen (SUN; of more than 45 mg/dl per day), IGFBP-3 was measured by ELISA using a commercially
available kit (Diagnostic Systems Laboratory, Webster,severe azotemia (SUN of more than 120 mg/dl), hyperna-
tremia or hyponatremia (160 , Na1 , 120 mm), fluid TX, USA). Both assays were performed in a central
laboratory. Iothalamate levels in serum and urine wereoverload or pulmonary edema (clinical examination or
chest x-ray), uremic pericarditis, or central nervous sys- measured in a central laboratory using previously de-
scribed methods [26]. All personnel who handled thetem abnormalities (clinical examination).
specimens or performed the chemical measurements
Measurement of glomerular filtration rate were blinded as to what treatment an individual patient
Iothalamate clearances were considered to indicate was given.
the GFR. Iothalamate clearances were measured in the
Statistical methodsmornings on the days indicated earlier in this article, and
the administration of rhIGF-I or placebo was delayed All data are presented as mean 6 1 sd unless stated
until the clearance measurement was completed. A se- otherwise. Differences between treatment groups and
rum and urine sample were obtained. Nonradioactive changes from baseline for each laboratory parameter
iothalamate, 1500 mg (5 ml of Conrayt 30; Mallinckrodt, were tested using analyses of variance (ANOVA) meth-
St. Louis, MO, USA), was injected intravenously as a ods. Significance of differences was assumed at a P of
bolus. A timed urine specimen was collected from an less than 0.05. Although the protocol specified that at
indwelling bladder catheter or by bladder voiding for entry creatinine clearance should be no greater than 25
the first 60 minutes after the iothalamate injection. This ml/min, there were nine patients with values outside of
one-hour urine collection was used for the measurement this range at baseline. Data from these patients were
of urinary creatinine and calculation of the creatinine excluded from the efficacy analysis.
clearance. This period of 60 minutes also allowed for
distribution of exogenously administered iothalamate
RESULTSinto the extracellular space. Subsequently, four consecu-
Thirty-five patients were randomized to receivetive 30-minute urine collections were obtained, and a
rhIGF-I treatment, and 37 subjects were randomized toserum sample was drawn at the beginning and end of
the placebo. Characteristics of these patients are showneach of these collection periods. Each of these latter
in Table 1. There were no differences between the twosamples was then used for the measurement of iothala-
groups with regard to age, gender or racial distribution,mate and calculation of the iothalamate clearance. Al-
body weight, APACHE II scores, or prevalence of oli-though renal failure is one of the risk factors for contrast
goanuria at baseline. However, the number of patientsmedium-induced acute nephropathy when large amounts
with hypotension or hemodynamic shock as the causeof radiation contrast media are given, the very small
for ARF was significantly greater in the rhIGF-I groupdose of iothalamate used as a GFR marker in this and
(42%) compared with the placebo group (27%, P ,other studies has not been associated with renal injury
0.05). All patients were hospitalized in intensive careand is believed to be safe.
units at the onset of the study. The primary causes of
Laboratory methods ARF are shown in Table 2. Sepsis and hypotension or
hemodynamic shock were the most commonly listedExcept as indicated later, the blood counts and serum
and urine chemistries were measured in the hospital clin- causes for ARF in both groups of patients. Surgery was
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Table 2. Primary cause of acute renal failureTable 1. Characteristics of patients with acute renal failure
rhIGF-I Placebo Primary cause of ARF rhIGF-1 Placebo
Sepsis 37% 35%Number of subjects 35 37
Age years 56.4617.2 55.8619.0 Hypotension 42% 27%
Surgery 11% 16%Gender, male:female % 46:54 59:41
Racial distribution % Aminoglycosides 3% 5%
Other/unknown 6% 16%Caucasian 57 73
African American 20 22
Other 23 5
Weight kg 86.2621.9 84.2627.3
Desirable body weight kg 62.167.9 63.769.2
APACHE II score 24.465.0 25.067.5 groups who were not oliguric at baseline (Fig. 1). Twelve
Number of patients with of 35 rhIGF-I patients and 11 out of 37 patients in the
baseline urine volume
placebo group were oliguric or anuric at baseline (that,500 ml/24 hours 12 11
$500 ml/24 hours 23 26 is, a daily urine volume less than 500 ml). Among the
oligoanuric rhIGF-I– and placebo-treated patients, urineData are mean 6 standard deviation.
volumes at baseline were 163 6 131 and 245 6 156
ml/24 hr, respectively. In both subgroups, daily urine
flow rates increased significantly during the 14 days of
the third most common primary cause for ARF in each study. This increase in urine volume above baseline val-
group. ues tended to be greater in the placebo group as com-
The mean and median number of injections of rhIGF-I pared with the rhIGF-I–treated oliguric subjects, al-
or placebo in individual patients averaged 20.3 6 8.7 though this trend was not statistically significant (P 5
(median, 24) injections in the rhIGF-I group and 19.6 6 0.246).
9.1 (median, 21) in the placebo group. The mean number Fifty evaluable subjects underwent iothalamate clear-
of injections was similar in the rhIGF-I and placebo ance measurements at baseline. This measurement was
groups and was less than the maximum total number of not performed in the remaining 22 patients because of
injections that were possible per patient, which was 28. insufficient urine flow rates to conduct the clearance
Reasons for the reduced number of injections included measurement. The iothalamate clearances at baseline
the death of subjects prior to finishing the 14 days of were 6.4 6 5.9 (median, 4.3) ml/min (N 5 23) in the
treatment (discussed later in this article); the mean dura- subjects receiving rhIGF-I and 8.7 6 7.2 (median, 6.3)
tion of treatment with rhIGF-I and placebo was 10.7 6 ml/min (N 5 27) in the placebo group (Fig. 2A). As
4.1 and 10.6 6 4.5 consecutive days, respectively. During expected, baseline iothalamate clearances were slightly
the treatment period, blood glucose concentrations be- greater in the rhIGF-I– and placebo-treated nonoliguric
low 60 mg/dl were observed on two occasions, one each patients than in those who were oliguric. In the rhIGF-I–
in the rhIGF-I–treated and the placebo-treated groups. and placebo-treated patients who during baseline were
Subjects treated with rhIGF-I received a cumulative dose oliguric, their median baseline iothalamate clearances
of 128 6 59 mg (median value, 137 mg) of this hormone were 0.5 ml/min (N 5 7) and 5.0 ml/min (N 5 8), respec-
during their entire study. There were no clinically impor- tively (Fig. 2B). In the oligoanuric as well as nonoliguric
tant side-effects that were attributable to rhIGF-I. patients in both the rhIGF-I and placebo groups, the
Serum IGF-I concentrations at baseline in most sub- iothalamate clearances tended to increase over the 14-
jects were below normal values (Table 3). Serum IGF-I day period of study (Fig. 2). There was no difference
levels at baseline were 124 6 67 and 102 6 53 ng/ml in in the rate of increase in iothalamate clearances from
the rhIGF-I and placebo-treated groups, respectively baseline or in the absolute values of these clearances at
(P 5 NS). During the treatment period, serum IGF-I any time point between the rhIGF-I versus the placebo
concentrations rose approximately four to five times in groups; this was also observed when the nonoliguric or
only the rhIGF-I patients and were unchanged in the oligoanuric patients were analyzed separately as well as
placebo-treated individuals (Table 3). for the nonoliguric and oligoanuric patients combined
(Fig. 2). Thus, treatment with rhIGF-I, as compared with
Renal function placebo, did not appear to accelerate the recovery of
At baseline, urine flow rates were 1116 6 1037 and GFR in patients with ARF.
1402 6 1183 ml/24 hr in the rhIGF-I and placebo-treated The foregoing findings are also supported by the creat-
groups, respectively. During each day of the treatment inine clearances in both study groups (Fig. 3). The creati-
period, urine volumes were not significantly different nine clearances were not different between the rhIGF-I
between either the entire group of rhIGF-I–treated pa- and placebo groups at baseline or at any time during the
tients versus placebo patients or between those patients treatment phase. When the creatinine clearances were
analyzed according to the daily urine flow, again therein the rhIGF-I (N 5 23) versus the placebo (N 5 26)
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Table 3. Serum chemistries in patients with acute renal failure treated with rhIGF-I or placebo
Day of study
Baseline 3 5 7 8 10 12 14
No. of patients in study
rhIGF-I 35 34 31 29 27 25 20 18
Placebo 37 34 32 29 27 25 20 18
Serum urea nitrogen mg/dla
Normal range: 10–20
rhIGF-I 62.6629.3 79.5 638.0 79.7 636.6 84.2 641.4 76.6 636.9 75.3 641.0 75.7 639.5 93.2 675.6
Placebo 76.0632.1 81.3 633.3 86.1 635.8 84.2 632.0 88.6 630.0 77.3 620.7 76.9 621.5 73.1 630.4
Serum creatinine mg/dla
Normal range: 0.5–1.2
rhIGF-I 6.266.7 4.7 62.3 4.3 62.4 4.2 62.8 5.3 66.7 3.8 62.5 3.7 62.5 4.0 62.4
Placebo 7.7611.8 7.0 612.7 4.3 62.1 3.8 61.8 4.0 61.8 3.6 61.7 3.2 61.6 2.8 61.4
Serum albumin g/dl
Normal range: 3.5–5.0
rhIGF-I 2.3360.82 2.16 60.67 2.35 60.81 2.24 60.76 — 2.3460.78 2.36 60.56 2.19 60.65
Placebo 2.5660.66 2.35 60.50 2.40 60.56 2.32 60.53 — 2.2260.62 2.24 60.59 2.31 60.59
Serum transferrin mg/dl
Normal range: 252–429
rhIGF-I 112647 117 649 112 643b 100633 — 110641c 108660 92 638b
Placebo 120655 123 655 130 650 130 652 — 148667 130 673 149 652
Day of Study
Baseline 4 9 13
Serum IGF-I ng/dl
Normal range: 170–230
rhIGF-I 124676 535 6213c 5766280c 6036230c
Placebo 102653 136 689 133 669 146 677
Data are mean 6 standard deviation.
a Excludes patients who underwent renal replacement therapy
b P # 0.05
c P 5 0.01 rhIGF-I vs. placebo
were no differences among the oligoanuric or nonoliguric the study (Table 3). In the oliguric patients, SUN in-
creased significantly more from baseline in the rhIGF-Ipatients between the two treatment groups (Fig. 3B).
The oliguric subjects who were randomized to receive group relative to the placebo-treated patients on days 10
and 11 (P , 0.05). The SUN did not decrease significantlyrhIGF-I tended to have lower creatinine clearances at
each time point, although the changes from baseline below baseline values during the two weeks of study,
even though the serum creatinine levels fell during thislevels in the rhIGF-I patients were not significantly dif-
ferent from the placebo groups. period of time.
At baseline, serum albumin levels were reduced belowAt baseline in the patients who had not received hemo-
dialysis or continuous ultrafiltration, serum creatinine normal in both the rhIGF-I and placebo-treated groups
and were 2.33 6 0.82 and 2.56 6 0.66 g/dl, respectivelyconcentrations were 6.2 6 6.7 and 7.7 6 11.8 mg/dl in
the rhIGF-I and placebo groups, respectively. In both (Table 3). During the treatment period, serum albumin
tended to be lower in the rhIGF-I group as comparedgroups, serum creatinine levels decreased substantially
over the 14-day period of study (Table 3). At each time with placebo, although the differences were not signifi-
point, there were no differences in the serum creatinine cant. Serum albumin concentrations did not change dur-
levels between the rhIGF-I– and placebo-treated pa- ing the course of study in either group (Table 3).
tients who did not receive dialysis or ultrafiltration (Ta- Serum transferrin concentrations were below normal
ble 3). at baseline and similar in the rhIGF-I– (112 6 47 mg/dl)
and placebo-treated groups (120 6 55 mg/dl; Table 3).
Metabolic data Serum transferrin levels tended to rise in the placebo
group, although not significantly. On days 5, 10, and 14At baseline in the patients who did not receive renal
replacement therapy, SUN levels were similar in the of treatment, serum transferrin concentrations decreased
significantly more in the rhIGF-I group as compared withrhIGF-I– (63 6 29 mg/dl) and placebo-treated (76 6 32
mg/dl) patients. The change from baseline in SUN was placebo (P , 0.05; Table 3). Serum transferrin tended
to be lower in the rhIGF-I versus the placebo-treatednot different in either the nonoliguric or total group of
rhIGF-I– versus placebo-treated patients on any day of patients both in those with APACHE II scores of less
Hirschberg et al: rhIGF-I in ARF2428
Fig. 2. (A) Glomerular filtration rate measured as clearance of iothala-
mate in all study participants with sufficient urine flow rates, receiving
Fig. 1. (A) Daily urine excretion in study participants randomly as- rhIGF-I (j; N 5 22) or placebo (h; N 5 27). Data are mean 6 sd.
signed to recombinant human insulin-like growth factor I (rhIGF-I; j; Values are not significantly different. (B) Glomerular filtration rate in
N 5 35) or placebo (h; N 5 37). Data are mean 6 sd. Values are not subjects who were oliguric at baseline and who had urine flow rates
significantly different. (B) Daily urine excretion in subjects who were sufficient for the measurement of iothalamate clearance treated with
oliguric or anuric at baseline (urine volume of less than 500 ml/24 hr) rhIGF-I (j; N 5 7) or placebo (h; N 5 8), respectively. Data are
and treated with rhIGF-I (j; N 5 12) or placebo (h; N 5 11), respec- mean 6 sd. Values are not significantly different.
tively. Data are mean 6 sd. Values are not significantly different.
at any time during the two weeks of study. At baseline,
than 25 and in those with APACHE II scores of 25 or IGFBP-3 levels were very low compared with the normal
greater. Indeed, serum transferrin decreased significantly reference range (3300 to 7260 ng/ml). At baseline,
more in the rhIGF-I–treated patients with APACHE II IGFBP-3 levels in the rhIGF-I group were 1804 6 125
scores of less than 25 on day 10 and in those with (sem) ng/ml in the patients subsequently receiving
APACHE II scores of 25 or greater on day 14. There rhIGF-I and 1842 6 143 (sem) ng/ml in the placebo
were no differences between the rhIGF-I– and placebo- subjects. Serum IGFBP-3 levels tended to decrease in
treated groups with regard to the change in 24-hour the rhIGF-I group toward the end of the two-week study,
urinary excretion of sodium, potassium, phosphorus, or but this trend was statistically not significant (Fig. 4B).
protein (data not shown).
Incidence of renal replacement therapy andSerum IGFBP-2 levels tended to increase during the
mortality ratefirst four days of study in subjects receiving rhIGF-I (Fig.
4A), but the values were not statistically different from Twenty patients in the rhIGF-I group (57%) and 17
placebo-treated patients (46%) underwent renal replace-baseline nor from those measured in the placebo group
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Fig. 4. Serum levels of IGF-binding protein-2 (A) and IGF-binding
protein-3 (B) in subjects receiving rhIGF-I (j) or placebo ( ). DataFig. 3. (A) Creatinine clearances in all subjects with sufficient urine
are mean 6 sem.flow rates, receiving rhIGF-I (j) or placebo (h), respectively. Data
are mean 6 sd. Values are not significantly different. (B) Creatinine
clearances in subjects who were oliguric at baseline receiving rhIGF-I
(j) or placebo (h). Data are mean 6 sd. Values are not significantly
different.
day. Overwhelming sepsis or cardiopulmonary failure
was the most commonly reported cause of death in both
groups.
ment therapy during the study (Table 4). Most of the
dialyzed patients had been treated with renal replace-
DISCUSSIONment therapy at or before baseline, indicating that ARF
In rats with experimental ARF, rhIGF-I can acceleratewas well established in these patients at the onset of this
the rate of recovery of renal function. The increase instudy. There was no difference in the number or type
renal function may begin within hours of commencingof renal replacement treatments provided to the two
rhIGF-I treatment [13], suggesting that at least part ofgroups of patients. Ten rhIGF-I–treated patients (29%)
the rise in renal function is due to hemodynamic factors,and 11 placebo-treated patients (30%) died during the
that is, an increase in renal blood flow and filtration14-day treatment phase of the study. The median num-
fraction leading to an increase in GFR [7]. RhIGF-Ibers of days of survival during treatment of these 21
also stimulates cell mitosis and can apparently promotepatients were seven and nine days, respectively. By day
healing of the structural nephron lesions associated with28 after the onset of the treatment phase, 12 rhIGF-I–
ischemic or some toxic injuries to the kidney. Moreover,and 12 placebo-treated patients had died. In the rhIGF-
rhIGF-I has anabolic effects. In rats with ARF, rhIGF-II–treated group, five oligoanuric and seven nonoliguric
reduces the urea nitrogen appearance (net urea genera-patients died on or before day 28. In the placebo group,
six oligoanuric and six nonoliguric patients died by this tion) and stimulates protein synthesis and suppresses
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Table 4. Renal replacement therapy ences between humans with ARF and rats with experi-
mental ARF. One such difference is that in rats, experi-rhIGF-I Placebo
(N 5 35) (N 5 37) mental ARF is created as an isolated disorder. Indeed,
No. of patients receiving RRT during when ARF is created surgically, the control rats are
study 20 17 usually sham operated and pair fasted so that the ARF
Days of RRT 9.2 66.8 6.4 66.0
can be investigated as an isolated event. In contrast, inRRT rate treatments per day 0.560.3 0.5 60.3
No. of patients who received RRT at or humans, ARF is often superimposed on severe clinical
before baseline 14 9 illnesses, frequently in a setting of profound metabolic
Days on RRT in patients started on RRT
disturbances.at or before baseline 10.3 67.0 7.8 67.2
In the patients in this study, the high APACHE IIData are mean 6 standard deviation. Abbreviation is: RRT, renal replacement
therapy (intermittent hemodialysis, continuous venovenous hemofiltration or scores and the causes of their ARF (Tables 1 and 2)
hemodiafiltration). indicate that they were very ill. The fact that all of the
patients were hospitalized in intensive care units at the
onset of the study and that their mean serum albumin
and transferrin concentrations were very low provideprotein degradation in skeletal muscle [13]. These find-
further support that these patients had other severe ill-ings provided a rationale for the use of rhIGF-I for the
nesses and disturbed metabolism. It is possible that thesetreatment of ARF in humans.
comorbid conditions might cause reinjury of nephrons,This clinical trial in patients with ARF does not indi-
prevent nephron healing, or abrogate the effects ofcate that rhIGF-I either improves the GFR or accelerates
rhIGF-I in these patients possibly by continued or recur-the rate of recovery of renal function. In fact, in surviving
rent sepsis, hemodynamic instability with episodes ofpatients who were oliguric at baseline and received
renal hypoperfusion, increased release of cytokines orrhIGF-I, improvements in GFR and urine flow rate
microbial toxins (for example, endotoxin), or the admin-tended to occur more slowly compared with placebo-
istration of nephrotoxic medicines.
treated subjects (Figs. 1B, 2B, and 3B). Moreover, treat-
The lack of bioactivity of the rhIGF-I batches does not
ment with rhIGF-I did not suppress the rate of rise of account for the failure to achieve beneficial therapeutic
the SUN or improve serum albumin or transferrin con- results in this trial. First, each batch of recombinant pep-
centrations. Administration of rhIGF-I to these patients tide had been tested for bioactivity in a mitogenicity
did not promote diuresis or affect the urinary excretion assay by the manufacturer. Second, in several experi-
of sodium, potassium, phosphorus, or protein. Other ad- mental and clinical studies using the same compound
verse events were minor and similar in the two groups, obtained from the same manufacturer, rhIGF-I in-
and serum antibodies to IGF-I were not detected in creased renal function and affected the metabolic param-
either group. eter [5–9, 13, 30, 32–34].
The lack of an effect of rhIGF-I on GFR or rate of Another possible explanation for the lack of effect
recovery of renal function could be due to several factors. of rhIGF-I is that the first dose of the hormone was
First, it is possible that rhIGF-I does not act on human administered as late as six days after the onset of ARF.
kidney as it does on rat kidney. Although this possibility This protocol design was used in order to allow time for
cannot be excluded, published research does not support the diagnosis of ARF, to obtain informed consent, and
this contention. In both normal rats and humans, the to perform baseline studies. In experimental rat models
administration of rhIGF-I increases renal blood flow and of ARF, rhIGF-I has been shown to enhance the recov-
GFR [5–9, 27]. In addition, in normal rats and in humans ery of renal function when it is first administered within
with chronic renal failure, the administration of rhIGF-I less than 24 hours after the induction of renal failure [10,
is reported to increase renal size [11, 28]. Moreover, in 12–16]. Whether rhIGF-I will enhance recovery when it
both rats and humans with chronic renal failure, rhIGF-I is first administered following a longer interval after the
stimulates anabolic processes [29, 30]. onset of ARF has not been previously tested. Thus, it is
Another possible cause for the lack of effect of possible that in this study the lack of improvement in
rhIGF-I is that the renal lesions of ARF in rats and renal function with rhIGF-I may be due to the delay in
humans are different. However, research suggests that inauguration of treatment.
both functional and anatomical manifestations of ische- Chronic renal failure induces resistance to the actions
mia- or nephrotoxin-induced ARF are similar in rats and of rhIGF-I in both rats and humans [29, 30, 35], and it
humans [31]. Indeed, experimental ARF in the rat is is possible that this resistance also occurs in ARF and
commonly used as a model to study the pathogenesis, contributes to the lack of effect of the recombinant pep-
pathophysiology, and anatomic pathology of ARF in tide in this study. However, the actions of rhIGF-I are
humans. reduced, but not abolished in chronic renal failure [29,
30]. Moreover, in rats with ARF, rhIGF-I enhances theOn the other hand, there are certain distinct differ-
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recovery of renal function at plasma levels similar to In summary, despite ample studies in research animals
that indicated that rhIGF-I accelerates the rate of recov-those observed in the patients in the current study [13].
The biological actions of IGF-I are also influenced ery of renal function in experimental ARF, this multicen-
ter, prospective, randomized, and placebo-controlledby seven IGF-binding proteins (IGFBPs) as well as the
IGF-I receptor [36]. In this study, IGFBP-3, which is the trial fails to demonstrate that rhIGF-I has similar effects
major carrier for serum IGF-I, was much reduced below in patients with established ARF.
normal levels in sera from patients receiving either
rhIGF-I or placebo (Fig. 4). In studies of rhIGF-I in ACKNOWLEDGMENTS
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subjects (Fig. 1B, 2B, and 3B). Although the differences
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